PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

SMC approves NHS funding for UCB’s Vimpat in children

Children living in Scotland with epilepsy will get NHS-funded treatment with UCB’s Vimpat following a green light from cost regulators.
The Scottish Medicines Consortium has accepted Vimpat (lacosamide) for NHS use as an adjunctive therapy for partial-onset (focal) seizures with or without secondary generalisation in children aged four years and older.
In Scotland there are around 55,000 people living with epilepsy but, despite its high prevalence, around 10-29 percent of children with the condition experience inadequate seizure control with currently available anti-epileptic drugs.
As such, the drug’s routine availability on the NHS in Scotland is “an important step forward for the management of paediatric epilepsy,” UCB noted.
The drug’s approval for younger patients in Europe in September last year was based on the principle of extrapolation of efficacy data in adults to children, supported by safety and pharmacokinetics data collected in a paediatric population, it was stressed.
“The acceptance of Vimpat for use in children aged four to 16 in NHS Scotland by the SMC is an important step forward for the management of paediatric epilepsy, a condition which can present significant challenges to children and their families,” said Jeff Wren, Executive Vice-President, Head of UCB’s Neurology Patient Value Unit.
“One of our key commitments at UCB is to improve the lives of people with epilepsy, and we are proud to be providing a proven treatment option for this highly impacted patient population.”
Vimpat was first launched in the EU in September 2008, as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents (16-18 years) with epilepsy.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026